Mankind Pharma Quarterly Results for Trading Insights

In Sept 2025, Mankind Pharma (MANKIND) reported revenue ₹3,791 Cr and net profit ₹520 Cr — revenue +19.5% YoY. For annual financials, live price and key ratios, visit MANKIND stock price BSE.

Latest Quarter Net Profit
₹520 Cr
QSept 2025
Quarterly Results

MANKIND Quarterly Results — Revenue, Profit & EPS Highlights

Mankind Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with MANKIND fundamental valuation to assess whether the stock is under or overvalued.

  • Revenue of ₹3,791 Cr in Sept 2025 (+13.7% vs Mar 2025, +19.5% vs Sept 2024)
  • Net Profit of ₹520 Cr in Sept 2025 (+22.4% vs Mar 2025, -21.1% vs Sept 2024)
  • EBITDA of ₹1,016 Cr in Sept 2025 (+8.9% vs Mar 2025)
  • Operating Margin of 25.0% in Sept 2025 (+3.0pp vs Mar 2025)
  • Earnings Per Share of ₹12.39 in Sept 2025 (+21.6% vs Mar 2025)

Mankind Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

MANKIND quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 3,791 3,333 3,653 3,643 3,173 13.7% 19.5%
Net Profit (₹ Cr) 520 425 445 414 659 - -
EBITDA (₹ Cr) 1,016 933 930 889 956 - -
EPS (₹) 12.39 10.19 10.62 9.90 16.31 - -
Operating Margin (%) 25.0% 22.0% 24.0% 23.0% 28.0% - -

MANKIND Share Price Trend — 1-Year Movement Across Quarterly Results

Mankind Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse MANKIND shareholding pattern to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 13.7%
EBITDA Margin 26.8%
Operating Margin 25.0%
ROE (Annual) 14.3%

Balance Sheet Highlights

Total Assets ₹27,760 Cr
Total Equity ₹14,568 Cr
Current Assets ₹6,988 Cr
Current Liabilities ₹7,528 Cr

Cash Flow Analysis

Operating Cash Flow ₹2,413 Cr
Investing Cash Flow ₹-12,624 Cr
Financing Cash Flow ₹10,233 Cr
Net Cash Flow ₹22 Cr

Current Market Data

Current Price ₹2077.40
Exchange NSE
Last Updated Apr 13, 2026

Revenue Trend (₹ Cr)

Dec 2025 3,643
Jun 2025 3,653
Mar 2025 3,333
Sept 2025 3,791

Net Profit Trend (₹ Cr)

Dec 2025 414
Jun 2025 445
Mar 2025 425
Sept 2025 520

Operating Margin Trend (%)

Dec 2025 23.0%
Jun 2025 24.0%
Mar 2025 22.0%
Sept 2025 25.0%

MANKIND vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Mankind Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹396,418.12 Cr 1652.2 14,875 3,125 +10.8% - 21.0% 127.1
Divis Laboratories
Sept 2025 		₹162,373.86 Cr 6070.0 2,860 689 +7.1% - 24.1% 233.7
Torrent Pharmaceuti…
Sept 2025 		₹140,630.85 Cr 4181.0 3,219 591 +11.3% - 18.4% 238.4
Lupin
Sept 2025 		₹106,664.75 Cr 2315.1 6,921 1,485 +23.2% - 21.5% 71.5
Dr Reddys Laborator…
Sept 2025 		₹102,844.71 Cr 1235.9 9,135 1,337 +1.1% - 14.6% 76.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores